Boston – Gunderson Dettmer advised Histogenics Corporation on its underwritten registered direct offering of 2,691,494 shares of its common stock at $2.35 per share for gross proceeds of $6.325 million, including the full exercise of the underwriter’s option to purchase additional shares. Corporate partner Marc Dupre, of counsel Keith Scherer and associates Albert Vanderlaan and John E. Maciejewski led the team advising Histogenics.

Canaccord served as the sole managing underwriter.

HSGX, which trades on the Nasdaq under the ticker symbol “HSGX,” is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis.